Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02333487 · ClinicalTrials.gov registry record · Phase 1
Positron Emission Tomography (PET) Study Investigating Dopamine and Serotonin Receptor Occupancy After Multiple Oral Dosing of Lu AF35700
A Phase 1 study, sponsored by H. Lundbeck A/S.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT02333487 is a Phase 1 study that has completed, run by H. Lundbeck A/S. The registered enrollment target is 22 participants.
The verdict
NCT02333487, a Phase 1 study, has completed, sponsored by H. Lundbeck A/S.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
The purpose of this PET study is to verify the binding of Lu AF35700 after multiple oral dosing at the dopamine and the serotonin receptors in male patients with schizophrenia.
Interventions
- DRUG Lu AF35700
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2014-12-30 |
| Est. Completion | 2016-02-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02333487
The ClinicalTrials.gov registry entry for NCT02333487 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lundbeck A/S, which has 72 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lu AF35700 is the first listed.
NCT02333487 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02333487 about?
NCT02333487 is a clinical study titled "Positron Emission Tomography (PET) Study Investigating Dopamine and Serotonin Receptor Occupancy After Multiple Oral Dosing of Lu AF35700". The purpose of this PET study is to verify the binding of Lu AF35700 after multiple oral dosing at the dopamine and the serotonin receptors in male patients with schizophrenia.
What is the current status of trial NCT02333487?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2014-12-30. Estimated completion is 2016-02-11.
What interventions are being tested in trial NCT02333487?
The interventions under investigation include: Lu AF35700 (DRUG).
Who is sponsoring clinical trial NCT02333487?
This trial is sponsored by H. Lundbeck A/S, which has 72 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.